Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Ocul Surf. 2019 Aug 16;18(1):47–55. doi: 10.1016/j.jtos.2019.08.002

Table 4:

Adverse events between month 12 and 24 in the extension study by system organ class, preferred term, and treatment group.

Treatment
Active 22 people Placebo 21 people
System Organ Class Preferred Term N Per 100 people N Per 100 people
Total 19 86.4 11 52.4
EAR AND LABYRINTH DISORDERS VERTIGO 1 4.5 -- --
EYE DISORDERS CONJUNCTIVAL HAEMORRHAGE 1 4.5 -- --
CONJUNCTIVAL IRRITATION -- -- 1 4.8
PHOTOPHOBIA -- -- 1 4.8
PHOTOPSIA 1 4.5 -- --
GASTROINTESTINAL DISORDERS DYSPEPSIA 1 4.5 -- --
HEPATOBILIARY DISORDERS HEPATOMEGALY 1 4.5 -- --
INFECTIONS AND INFESTATIONS BRONCHITIS 1 4.5 -- --
GINGIVAL INFECTION -- -- 1 4.8
INFECTION 1 4.5 -- --
LUNG INFECTION 1 4.5 -- --
NASAL ABSCESS 1 4.5 -- --
NASOPHARYNGITIS 1 4.5 -- --
TOOTH INFECTION 1 4.5 -- --
URINARY TRACT INFECTION 1 4.5 -- --
INJURY, POISONING AND PROCEDURAL COMPLICATIONS ARTHROPOD BITE 1 4.5 -- --
EPICONDYLITIS -- -- 1 4.8
FRACTURE 1 4.5 -- --
INVESTIGATIONS BLOOD CALCIUM INCREASED 1 4.5 -- --
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS BACK PAIN 1 4.5 1 4.8
NECK PAIN -- -- 1 4.8
TRIGGER FINGER 1 4.5 -- --
NERVOUS SYSTEM DISORDERS DIZZINESS -- -- 1 4.8
SCIATICA -- -- 1 4.8
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS ALLERGIC COUGH 1 4.5 -- --
COUGH 1 4.5 -- --
SURGICAL AND MEDICAL PROCEDURES CATARACT OPERATION -- -- 2 9.5
VASCULAR DISORDERS BLOOD PRESSURE FLUCTUATION -- -- 1 4.8